{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1410","upperLimit":"10700","value":"3490"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"260"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants received lenvatinib 24 mg, hard capsule, orally, once daily, until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Randomization Phase: Lenvatinib 24 mg"}],"paramType":"MEDIAN","populationDescription":"The PK analysis set included all the participants who received at least one dose of study drug and had evaluable PK data.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Days 1 and 15: 0-10 hours postdose; Cycle 2 Day 1: 0-12 hour postdose","title":"Pharmacokinetic (PK) Profile of Lenvatinib: Area Under the Plasma Concentration Curve","type":"SECONDARY","unitOfMeasure":"nanogram*hour per milliliter (ng*h/mL)"}